Page last updated: 2024-12-05

4-phenylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

4-Phenylpyridine is a heterocyclic compound with a pyridine ring substituted with a phenyl group at the 4-position. It is a crystalline solid that is used as a reagent in organic synthesis. 4-Phenylpyridine is also known to be a potent inhibitor of the enzyme monoamine oxidase. This enzyme plays a role in the breakdown of neurotransmitters such as dopamine, serotonin, and norepinephrine. 4-Phenylpyridine is also known to be a potential neuroprotectant. Research has shown that 4-phenylpyridine can protect nerve cells from damage caused by toxins and other factors. 4-Phenylpyridine is studied for its potential therapeutic applications in the treatment of neurological disorders, such as Parkinson’s disease, Alzheimer’s disease, and depression. '

Cross-References

ID SourceID
PubMed CID13651
CHEMBL ID109074
CHEBI ID173662
SCHEMBL ID124353
SCHEMBL ID19003057
MeSH IDM0146425

Synonyms (48)

Synonym
AC-5099
452kd9ycg7 ,
unii-452kd9ycg7
5-20-07-00549 (beilstein handbook reference)
CHEBI:173662
4-phenylpyridine
939-23-1
pyridine, 4-phenyl-
nsc70375
nsc-70375
p-phenylpyridine
nsc 70375
brn 0110490
nsc 77935
einecs 213-357-4
nsc77935
nsc-77935
inchi=1/c11h9n/c1-2-4-10(5-3-1)11-6-8-12-9-7-11/h1-9
4-phenylpyridine, 97%
bdbm50121955
MLS002206281
smr000112292
CHEMBL109074 ,
4-phenyl-pyridine
P0162
AKOS005255288
NCGC00247406-01
HMS2268O18
pyridine, phenyl-
52642-16-7
FT-0619412
SCHEMBL124353
?-phenylpyridine
4-phenylpyridin
4-aza-1,1'-biphenyl
W-100225
5sh ,
mfcd00006420
DTXSID5022140
SCHEMBL19003057
phenyl-pyridine
4-pyridylbenzene
SY021647
DS-14724
CS-W018018
AMY32754
Q27258800
EN300-49165

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Additional experiments showed that 4PP pretreatment reduced striatal concentrations of 1-methyl-4-phenylpyridinium ion (MPP+) - the putative toxic biotransformation product of MPTP, and that the concentration of this metabolite closely mirrored striatal DA depletion in MPTP-treated mice."( 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity.
DeLanney, LE; Irwin, I; Langston, JW, 1987
)
1.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylpyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
Guanine nucleotide-binding protein GHomo sapiens (human)Potency2.23871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Klebsiella pneumoniaeKd1,000.00000.85000.85000.8500AID1320842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
amino acid metabolic processDihydropteridine reductaseHomo sapiens (human)
dihydrobiopterin metabolic processDihydropteridine reductaseHomo sapiens (human)
tetrahydrobiopterin biosynthetic processDihydropteridine reductaseHomo sapiens (human)
L-phenylalanine catabolic processDihydropteridine reductaseHomo sapiens (human)
chromatin remodelingPeregrinHomo sapiens (human)
regulation of DNA-templated transcriptionPeregrinHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeregrinHomo sapiens (human)
regulation of developmental processPeregrinHomo sapiens (human)
regulation of hemopoiesisPeregrinHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeregrinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
6,7-dihydropteridine reductase activityDihydropteridine reductaseHomo sapiens (human)
electron transfer activityDihydropteridine reductaseHomo sapiens (human)
NADH bindingDihydropteridine reductaseHomo sapiens (human)
NADPH bindingDihydropteridine reductaseHomo sapiens (human)
histone H4K5 acetyltransferase activityPeregrinHomo sapiens (human)
histone H4K8 acetyltransferase activityPeregrinHomo sapiens (human)
histone H4K12 acetyltransferase activityPeregrinHomo sapiens (human)
DNA bindingPeregrinHomo sapiens (human)
protein bindingPeregrinHomo sapiens (human)
acetyltransferase activator activityPeregrinHomo sapiens (human)
metal ion bindingPeregrinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
cytoplasmDihydropteridine reductaseHomo sapiens (human)
cytosolDihydropteridine reductaseHomo sapiens (human)
extracellular exosomeDihydropteridine reductaseHomo sapiens (human)
cytoplasmDihydropteridine reductaseHomo sapiens (human)
nucleusPeregrinHomo sapiens (human)
nucleoplasmPeregrinHomo sapiens (human)
cytoplasmPeregrinHomo sapiens (human)
cytosolPeregrinHomo sapiens (human)
plasma membranePeregrinHomo sapiens (human)
MOZ/MORF histone acetyltransferase complexPeregrinHomo sapiens (human)
histone acetyltransferase complexPeregrinHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1320842Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as dissociation constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID208330Binding to stromelysin (MMP-3) in the presence of acetohydroxamic acid2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
AID56920Inhibitory activity against rat striatal synaptosomes Dihydrodipicolinate reductase (DHPR)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and dihydropteridine reductase inhibitory effects of potential metabolites of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
AID1775064Inhibition of recombinant human IDO1 expressed in Escherichia coli Rosetta (DE3) cells assessed as reduction in kynurenine production using L-tryptophan as substrate incubated for 20 mins by HPLC analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
AID208329Binding to stromelysin (MMP-3) in the presence of 1-Napthohydroxamate2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
AID56917Inhibitory activity against human liver Dihydrodipicolinate reductase (DHPR)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and dihydropteridine reductase inhibitory effects of potential metabolites of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
AID1320843Inhibition of native signal containing Klebsiella pneumoniae OXA-48 using nitrocefin substrate pre-incubated for 5 mins before substrate addition2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID1308809Binding affinity to recombinant GST-tagged human BRPF1 expressed in Escherichia coli BL21 (DE3) after 1 hr by qPCR-based BromoScan assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Twenty Crystal Structures of Bromodomain and PHD Finger Containing Protein 1 (BRPF1)/Ligand Complexes Reveal Conserved Binding Motifs and Rare Interactions.
AID687183Inhibition of human recombinant N-terminal His-tagged IDO1 (Ala2 to Gly403) overexpressed in Escherichia coli BL21 at 1 mM at pH 6.5 after 60 mins by HPLC analysis2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (14.71)18.7374
1990's7 (20.59)18.2507
2000's6 (17.65)29.6817
2010's11 (32.35)24.3611
2020's5 (14.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.78 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]